BENYLIN (diphenhydramine hydrochloride) by Pfizer is clinical pharmacology diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
BENYLIN is an oral syrup formulation of diphenhydramine hydrochloride, a first-generation antihistamine used to treat allergic reactions, urticaria, and cold symptoms. The drug works by competing with histamine for cell receptor sites, with additional anticholinergic and sedative properties that contribute to its therapeutic effect.
Pre-launch stage indicates developing commercial infrastructure and team building; career opportunities focused on launch planning and market entry strategy.
CLINICAL PHARMACOLOGY Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells. Diphenhydramine hydrochloride in the injectable form has a rapid onset of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects
Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination
Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
Worked on BENYLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BENYLIN in pre-launch phase offers exposure to launch execution, go-to-market strategy, and Pfizer's commercial infrastructure in a competitive OTC/generic market. Career growth is tied to launch success and subsequent market penetration rather than long-term patent-driven growth.